Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Clinical trial NCT04669496 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04669496
Sponsor: Shanghai Zhongshan Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma PD1 Antibody Lenvatinib Gemox Chemotherapy

Start date: 2021-01-20
Primary completion: 2025-04-30
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.